HRP20110540T1 - Antibakterijski derivati kinolina - Google Patents

Antibakterijski derivati kinolina Download PDF

Info

Publication number
HRP20110540T1
HRP20110540T1 HR20110540T HRP20110540T HRP20110540T1 HR P20110540 T1 HRP20110540 T1 HR P20110540T1 HR 20110540 T HR20110540 T HR 20110540T HR P20110540 T HRP20110540 T HR P20110540T HR P20110540 T1 HRP20110540 T1 HR P20110540T1
Authority
HR
Croatia
Prior art keywords
alkyl
aryl
mono
het
compound according
Prior art date
Application number
HR20110540T
Other languages
English (en)
Inventor
Emile Georges Guillemont J�r�me
Jozef Lodewijk Marcel Andries Koenraad
Koul Anil
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of HRP20110540T1 publication Critical patent/HRP20110540T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Spoj, naznačen time, da je prikazan formulom (Ia) ili (Ib) uključujući i bilo koji njegov stereokemijski izomerni oblik, pri čemu p je cijeli broj koji je jednak 1, 2, 3 ili 4; q je cijeli broj koji je jednak nuli, 1, 2, 3 ili 4; R1 je vodik, cijano, formil, karboksil, halo, alkil, C2-6alkenil, C2-6alkinil, haloalkil, hidroksi, alkiloksi, alkiltio, alkiltioalkil -C=N-OR11, amino, mono ili di(alkil)amino, aminoalkil, mono ili di(alkil)aminoalkil, alkilkarbonilaminoalkil, aminokarbonil, mono ili di(alkil)aminokarbonil, arilalkil, arilkarbonil, R5aR4aNalkil, di(aril)alkil, aril, R5aR4aN-, R5aR4aN-C(=O)- ili Het; R2 je vodik, alkiloksi, aril, ariloksi, hidroksi, merkapto, alkiloksialkiloksi, alkiltio, mono ili di(alkil)amino, pirolidino ili radikal formule pri čemu Y je CH2, O, S, NH ili N-alkil; R3 je alkil, arilalkil, aril-O-alkil, aril-alkil-O-alkil, aril, aril-aril, Het, Het-alkil, Het-O-alkil, Het-alkil-O-alkil ili R4 i R5 svaki nezavisno je vodik; alkil; alkiloksialkil; arilalkil; Het-alkil; mono- ili dialkilaminoalkil; biciklo[2.2.1]heptil; Het; aril; ili -C(=NH)-NH2; iliR4 i R5 zajedno sa atomom dušika, na kojeg su vezani, tvore radikal koji je odabran iz skupine koja sadrži pirolidino, piperidin, piperazino, morfolino, 4-tiomorfolino, 1,1-dioksid-tiomorfolinil, azetidinil, 2,3-dihidroizoindol-1-il, tiazolidin-3-il, 1,2,3,6-tetrahidropiridil, heksahidro-1H-azepinil, heksahidro-1H-1,4-diazepinil, heksahidro-1,4-oksazepinil, 1,2,3,4-tetrahidroizokinolin-2-il, 2,5-diazabiciklo[2.2,1]heptil, pirolinil, pirolil, imidazolidinil, pirazolidinil, 2-imidazolinil, 2-pirazolinil, imidazolil, pirazolil, triazolil, piridinil, piridazinil, pirimidinil, pirazinil i triazinil, te je svaki radikal proizvoljno supstituiran sa 1, 2, 3 ili 4 supstituenata, te je svaki supstituent nezavisno odabran od alkila, haloalkila, alkilkarbonila, halo, arilalkila, hidroksi, alkiloksi, amino, mono- ili dialkilamino, aminoalkila, mono- ili dialkilaminoalkila, alkiltio, alkiltioalkila, arila, piridila, pirimidinila, piperidinila koji je proizvoljno supstituiran sa alkilom ili pirolidinilom koji je proizvoljno supstituiran sa arilalkilom; R4a i R5a zajedno sa atomom dušika, na kojeg su spojeni, tvore radikal koji je odabran iz skupine koja sadrži pirolidino, piperidino, piperazino, morfolino, 4-tiomorfolino, 2,3-dihidroizoindol-1-il, tiazolidin-3-il, 1,2,3,6-tetrahidropiridil, heksahidro-1H-azepinil, heksahidro-1H-1,4-diazepinil, heksahidro-1,4-oksazepinil, 1,2,3,4-tetrahidroizokinolin-2-il, pirolinil, pirolil, imidazolidinil, pirazolidinil, 2-imidazolinil, 2-pirazolinil, imidazolil, pirazolil triazolil, piridinil, piridazinil, pirimidinil, pirazinil i triazinil, te je svaki radikal proizvoljno supstituiran sa 1, 2, 3 ili 4 supstituenata, te je svaki supstituent nezavisno odabran od alkila, haloalkila, halo, arilalkila, hidroksi, alkiloksi, amino, mono- ili dialkilamino, alkiltio, alkiltioalkila, arila, piridila ili pirimidinila; R7 je vodik, halo, alkil, aril ili Het; R8 je

Claims (21)

1. Spoj, naznačen time, da je prikazan formulom (Ia) ili (Ib) [image] [image] uključujući i bilo koji njegov stereokemijski izomerni oblik, pri čemu p je cijeli broj koji je jednak 1, 2, 3 ili 4; q je cijeli broj koji je jednak nuli, 1, 2, 3 ili 4; R1 je vodik, cijano, formil, karboksil, halo, alkil, C2-6alkenil, C2-6alkinil, haloalkil, hidroksi, alkiloksi, alkiltio, alkiltioalkil -C=N-OR11, amino, mono ili di(alkil)amino, aminoalkil, mono ili di(alkil)aminoalkil, alkilkarbonilaminoalkil, aminokarbonil, mono ili di(alkil)aminokarbonil, arilalkil, arilkarbonil, R5aR4aNalkil, di(aril)alkil, aril, R5aR4aN-, R5aR4aN-C(=O)- ili Het; R2 je vodik, alkiloksi, aril, ariloksi, hidroksi, merkapto, alkiloksialkiloksi, alkiltio, mono ili di(alkil)amino, pirolidino ili radikal formule [image] pri čemu Y je CH2, O, S, NH ili N-alkil; R3 je alkil, arilalkil, aril-O-alkil, aril-alkil-O-alkil, aril, aril-aril, Het, Het-alkil, Het-O-alkil, Het-alkil-O-alkil ili [image] R4 i R5 svaki nezavisno je vodik; alkil; alkiloksialkil; arilalkil; Het-alkil; mono- ili dialkilaminoalkil; biciklo[2.2.1]heptil; Het; aril; ili -C(=NH)-NH2; ili R4 i R5 zajedno sa atomom dušika, na kojeg su vezani, tvore radikal koji je odabran iz skupine koja sadrži pirolidino, piperidin, piperazino, morfolino, 4-tiomorfolino, 1,1-dioksid-tiomorfolinil, azetidinil, 2,3-dihidroizoindol-1-il, tiazolidin-3-il, 1,2,3,6-tetrahidropiridil, heksahidro-1H-azepinil, heksahidro-1H-1,4-diazepinil, heksahidro-1,4-oksazepinil, 1,2,3,4-tetrahidroizokinolin-2-il, 2,5-diazabiciklo[2.2,1]heptil, pirolinil, pirolil, imidazolidinil, pirazolidinil, 2-imidazolinil, 2-pirazolinil, imidazolil, pirazolil, triazolil, piridinil, piridazinil, pirimidinil, pirazinil i triazinil, te je svaki radikal proizvoljno supstituiran sa 1, 2, 3 ili 4 supstituenata, te je svaki supstituent nezavisno odabran od alkila, haloalkila, alkilkarbonila, halo, arilalkila, hidroksi, alkiloksi, amino, mono- ili dialkilamino, aminoalkila, mono- ili dialkilaminoalkila, alkiltio, alkiltioalkila, arila, piridila, pirimidinila, piperidinila koji je proizvoljno supstituiran sa alkilom ili pirolidinilom koji je proizvoljno supstituiran sa arilalkilom; R4a i R5a zajedno sa atomom dušika, na kojeg su spojeni, tvore radikal koji je odabran iz skupine koja sadrži pirolidino, piperidino, piperazino, morfolino, 4-tiomorfolino, 2,3-dihidroizoindol-1-il, tiazolidin-3-il, 1,2,3,6-tetrahidropiridil, heksahidro-1H-azepinil, heksahidro-1H-1,4-diazepinil, heksahidro-1,4-oksazepinil, 1,2,3,4-tetrahidroizokinolin-2-il, pirolinil, pirolil, imidazolidinil, pirazolidinil, 2-imidazolinil, 2-pirazolinil, imidazolil, pirazolil triazolil, piridinil, piridazinil, pirimidinil, pirazinil i triazinil, te je svaki radikal proizvoljno supstituiran sa 1, 2, 3 ili 4 supstituenata, te je svaki supstituent nezavisno odabran od alkila, haloalkila, halo, arilalkila, hidroksi, alkiloksi, amino, mono- ili dialkilamino, alkiltio, alkiltioalkila, arila, piridila ili pirimidinila; R7 je vodik, halo, alkil, aril ili Het; R8 je vodik ili alkil; R9 je okso; ili R8 i R9 zajedno tvore radikal -CH=CH-N=; R11 je vodik ili alkil; aril je homocikal koji je odabran od fenila, naftila, acenaftila ili tetrahidronaftila, te je svaki od njih proizvoljno supstituiran sa 1, 2 ili 3 supstituenata, a svaki supstituent je nezavisno odabran od hidroksi, halo, cijano, nitro, amino, mono- ili dialkilamino, alkila, C2-6alkenila koji je proizvoljno supstituiran sa fenilom, haloalkilom, alkiloksi, haloalkiloksi, karboksilom, alkiloksikarbonilom, aminokarbonilom, morfolinilom ili mono- ili dialkilaminokarbonilom; Het je monociklički heterocikal koji je odabran iz N-fenoksipiperidinila, piperidinila, pirolila, pirazolila, imidazolila, furanila, tienila, oksazolila, izoksazolila, tiazolila, izotiazolila, piridinila, pirimidinila, pirazinila ili piridazinila; ili biciklički heterocikal koji je odabran od kvinolinila, kvinoksalinila, indolila, benzimidazolila, benzoksazolila, benzizoksazolila, benzotiazolila, benzizotiazolila, benzofuranila, benzotienila, 2,3-dihidrobenzo[1,4]dioksinila ili benzo[1,3]dioksolila; a svaki monociklički ili biciklički heterocikal je proizvoljno supstituiran sa 1, 2 ili 3 supstituenata, te je svaki supstituent nezavisno odabran od halo, hidroksi, alkila ili alkiloksi; njegov N-oksid, njegova farmaceutski prihvatljiva sol ili njegov solvat.
2. Spoj prema zahtjevu 1, naznačen time, da R3 je alkil, arilalkil, aril-O-alkil, aril-alkil-O-alkil, aril, Het, Het-alkil, Het-O-alkil, Het-alkil-O-alkil ili [image] R4 i R5 svaki nezavisno je vodik; alkil; alkiloksialkil; arilalkil; Het-alkil; mono- ili dialkilaminoalkil; Het; aril; ili -C(=NH)-NH2; ili R4 i R5 zajedno sa atomom dušika, na kojeg su spojeni, tvore radikal koji je odabran iz skupine koja sadrži pirolidino, piperidino, piperazino, morfolino, 4-tiomorfolino, 2,3-dihidroizoindol-1-il, tiazolidin-3-il, 1,2,3,6-tetrahidropiridil, heksahidro-1H-azepinil, heksahidro-1H-1,4-diazepinil, heksahidro-1,4-oksazepinil, 1,2,3,4-tetrahidroizokinolin-2-il, 2,5-diazabiciklo[2.2.1]heptil, pirolinil, pirolil, imidazolidinil, pirazolidinil, 2-imidazolinil, 2-pirazolinil, imidazolil, pirazolil, triazolil, piridinil, piridazinil, pirimidinil, pirazinil i triazinil, te je svaki radikal proizvoljno supstituiran sa 1,2, 3 ili 4 supstituenata, a svaki supstituent je nezavisno odabran od alkila, haloalkila, alkilkarbonila, halo, arilalkila, hidroksi, alkiloksi, amino, mono- ili dialkilamino, alkiltio, alkiltioalkila, arila, piridila, pirimidinila, piperidinila ili pirolidinila koji je proizvoljno supstituiran sa arilalkilom; aril je homocikal koji je odabran od fenila, naftila, acenaftila ili tetrahidronaftila, te je svaki od njih proizvoljno supstituiran sa 1, 2 ili 3 supstituenata, a svaki supstituent je nezavisno odabran od hidroksi, halo, cijano, nitro, amino, mono- ili dialkilamino, alkila, haloalkila, alkiloksi, haloalkiloksi, karboksila, alkiloksikarbonila, aminokarbonila, morfolinila ili mono- ili dialkilaminokarbonila.
3. Spoj prema zahtjevu 1 ili 2, naznačen time, da alkil predstavlja C1-6alkil.
4. Spoj prema bilo kojem od prethodnih zahtjeva, naznačen time, da R1 je halo, Het ili aril.
5. Spoj prema zahtjevu 4, naznačen time, da R1 je halo.
6. Spoj prema bilo kojem od prethodnih zahtjeva, naznačen time, da je p jednako 1.
7. Spoj prema bilo kojem od prethodnih zahtjeva, naznačen time, da R2 je C1-6alkiloksi.
8. Spoj prema bilo kojem od prethodnih zahtjeva, naznačen time, da R3 je aril.
9. Spoj prema bilo kojem od prethodnih zahtjeva, naznačen time, da je q jednako 2, 3 ili 4.
10. Spoj prema bilo kojem od prethodnih zahtjeva, naznačen time, da R4 i R5 predstavljaju C1-6alkil.
11. Spoj prema bilo kojem od prethodnih zahtjeva, naznačen time, da R7 je vodik.
12. Spoj prema bilo kojem od prethodnih zahtjeva, naznačen time, da navedeni spoj je spoj formule (Ia).
13. Spoj prema zahtjevu 12, naznačen time, da R1 je halo; R2 je C1-6alkiloksi; R8 je aril; R4 i R5 su C1-6alkil; R7 je vodik; q je 2, 3 ili 4; te p je 1.
14. Spoj prema bilo kojem od prethodnih zahtjeva, naznačen time, da se navedeni spoj upotrebljava kao lijek.
15. Spoj prema bilo kojem od zahtjeva 1 do 13, naznačen time, da se navedeni spoj upotrebljava kao lijek za liječenje bakterijske infekcije uključujući i mikobakterijsku infekciju.
16. Farmaceutski pripravak, naznačen time, da sadrži farmaceutski prihvatljivi nosač, te kao aktivan sastojak, terapeutski učinkovitu količinu spoja kako je definirano u bilo kojem od zahtjeva 1 do 13.
17. Spoj prema zahtjevu 15, naznačen time, da navedena bakterijska infekcija je infekcija sa gram-pozitivnom bakterijom.
18. Spoj prema zahtjevu 15, naznačen time, da navedena gram-pozitivna bakterija je Streptococcus pneumoniae ili Staphilococcus aureus.
19. Kombinacija, naznačena time, da sadrži (a) spoj prema bilo kojem od zahtjeva od 1 do 13 i (b) jedno ili više drugih antibakterijskih sredstava.
20. Produkt, naznačen time, da sadrži (a) spoj prema bilo kojem od zahtjeva od 1 do 13 i (b) jedno ili više drugih antibakterijskih sredstava, u obliku kombiniranog pripravka za simultanu, odvojenu ili sekvencijalnu upotrebu kod liječenja bakterijske infekcije.
21. Spoj prema zahtjevu 18, naznačen time, da je navedena gram-pozitivna bakterija Staphilococcus aureus koji je otporan na meticilin.
HR20110540T 2006-12-06 2011-07-21 Antibakterijski derivati kinolina HRP20110540T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06125529 2006-12-06
PCT/EP2007/063316 WO2008068270A1 (en) 2006-12-06 2007-12-04 Antibacterial quinoline derivatives

Publications (1)

Publication Number Publication Date
HRP20110540T1 true HRP20110540T1 (hr) 2011-08-31

Family

ID=38124123

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20110540T HRP20110540T1 (hr) 2006-12-06 2011-07-21 Antibakterijski derivati kinolina

Country Status (29)

Country Link
US (1) US20110166179A1 (hr)
EP (1) EP2099759B1 (hr)
JP (1) JP5356246B2 (hr)
KR (1) KR101526175B1 (hr)
CN (1) CN101553471B (hr)
AR (1) AR064152A1 (hr)
AT (1) ATE509915T1 (hr)
AU (1) AU2007328890B2 (hr)
BR (1) BRPI0720133A2 (hr)
CA (1) CA2669829C (hr)
CL (1) CL2007003517A1 (hr)
CY (1) CY1112230T1 (hr)
DK (1) DK2099759T3 (hr)
ES (1) ES2366062T3 (hr)
HK (1) HK1137431A1 (hr)
HR (1) HRP20110540T1 (hr)
IL (1) IL199084A0 (hr)
JO (1) JO2725B1 (hr)
ME (1) ME01245B (hr)
MX (1) MX2009005981A (hr)
NO (1) NO342774B1 (hr)
NZ (1) NZ577069A (hr)
PL (1) PL2099759T3 (hr)
PT (1) PT2099759E (hr)
RS (1) RS51848B (hr)
RU (1) RU2439058C2 (hr)
SI (1) SI2099759T1 (hr)
TW (1) TWI487525B (hr)
WO (1) WO2008068270A1 (hr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE041355T2 (hu) * 2010-01-04 2019-05-28 Nippon Soda Co Nitrogén-tartalmú heterociklusos vegyület és mezõgazdasági/kertészeti csíraölõ
AR086411A1 (es) 2011-05-20 2013-12-11 Nippon Soda Co Compuesto heterociclico conteniendo nitrogeno y fungicida para el uso en agricultura y jardineria
RU2486175C2 (ru) * 2011-09-12 2013-06-27 Закрытое Акционерное Общество "Фарм-Синтез" Производные хинолина, в частности 5,6,7-замещенные 1-(2-хлорхинолин-3-ил)-4-диметиламино-2-(нафталин-1-ил)-1-фенилбутан-2-олы, способ получения и применение соединений
DK2841425T3 (en) * 2012-04-27 2016-06-27 Janssen Pharmaceutica Nv ANTIBACTERIAL QUINOLIN DERIVATIVES
EA038350B1 (ru) 2012-04-27 2021-08-12 Янссен Фармацевтика Нв Антибактериальные хинолиновые производные
CN105232540A (zh) * 2015-09-29 2016-01-13 王洪燕 一种治疗烧伤后感染的药物组合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1527050T1 (sl) * 2002-07-25 2010-08-31 Janssen Pharmaceutica Nv Kinolinski derivati in njihova uporaba kot mikobakterijski inhibitorji
BRPI0507065B8 (pt) * 2004-01-23 2021-05-25 Janssen Pharmaceutica Nv derivados de quinolina, composição que os compreende, seu processo de preparação e seu uso como inibidores micobacterianos
JO2524B1 (en) * 2004-05-28 2010-03-17 جانسن فارمسيتكا ان في Use of substituted quinoline derivatives to treat drug-resistant microbial diseases
EE05394B1 (et) * 2004-12-24 2011-04-15 Janssen Pharmaceutica N.V. Kinoliinihendid kasutamiseks latentse tuberkuloosi ravis

Also Published As

Publication number Publication date
TWI487525B (zh) 2015-06-11
NO20092547L (no) 2009-08-24
CA2669829A1 (en) 2008-06-12
TW200845986A (en) 2008-12-01
KR20090086611A (ko) 2009-08-13
MX2009005981A (es) 2009-06-16
BRPI0720133A2 (pt) 2014-02-04
CA2669829C (en) 2016-08-30
CL2007003517A1 (es) 2008-07-11
JP5356246B2 (ja) 2013-12-04
CN101553471A (zh) 2009-10-07
RU2009125520A (ru) 2011-01-20
ME01245B (me) 2013-06-20
ATE509915T1 (de) 2011-06-15
AU2007328890A1 (en) 2008-06-12
EP2099759B1 (en) 2011-05-18
RU2439058C2 (ru) 2012-01-10
DK2099759T3 (da) 2011-08-15
RS51848B (en) 2012-02-29
EP2099759A1 (en) 2009-09-16
SI2099759T1 (sl) 2011-09-30
CN101553471B (zh) 2013-04-03
AR064152A1 (es) 2009-03-18
AU2007328890B2 (en) 2013-03-14
NO342774B1 (no) 2018-08-06
JO2725B1 (en) 2013-09-15
WO2008068270A1 (en) 2008-06-12
PL2099759T3 (pl) 2011-09-30
CY1112230T1 (el) 2015-12-09
PT2099759E (pt) 2011-07-27
ES2366062T3 (es) 2011-10-14
JP2010511671A (ja) 2010-04-15
KR101526175B1 (ko) 2015-06-05
HK1137431A1 (en) 2010-07-30
IL199084A0 (en) 2010-03-28
US20110166179A1 (en) 2011-07-07
NZ577069A (en) 2011-09-30

Similar Documents

Publication Publication Date Title
HRP20160585T1 (hr) Antibakterijski derivati kinolina
HRP20110540T1 (hr) Antibakterijski derivati kinolina
HRP20100428T1 (hr) Antibakterijski derivati kvinolina
HRP20131116T1 (hr) Derivati kinolina kao antibakterijska sredstva
JP2010511667A5 (hr)
HRP20100696T1 (hr) Hiv inhibirajuci 5-(hidroksimetilen i aminometilen) supstituirani pirimidini
MX2009007006A (es) Pirimidinas 5,6-sustituidas inhibidoras del virus de inmunodeficiencia humana.
HRP20110392T1 (hr) Derivati kinolina za liječenje latentne tuberkuloze
HRP20170044T1 (hr) Derivati kinolina kao antibakterijska sredstva
HRP20160252T1 (hr) C-4" položaj supstituiranog derivata makrolida
HRP20080307T3 (hr) Uporaba supstituiranih kinolinskih derivata za tretman bolesti uzrokovanih mikobakterijama otpornima na lijekove
RS52431B (en) QUINOLINE DERIVATIVES AND THEIR USE AS MYCOBACTERIAL INHIBITORS
JP2010511668A5 (hr)
HRP20160065T1 (hr) Spojevi piridazinona
HRP20140206T1 (hr) Derivati kinolina kao antibakterijska sredstva
HRP20120910T1 (hr) Derivati kinolina kao antibakterijska sredstva
CA2478229A1 (en) Pyridinoylpiperidines as 5-ht1f agonists
HRP20151308T1 (hr) Antibakterijski derivati kinolina
MY159560A (en) Quinoline derivatives as antibacterial agents
HRP20161704T1 (hr) Derivati kinolina kao antibakterijska sredstva
JP2010511671A5 (hr)
HRP20120912T1 (hr) Derivati kinolina kao antibakterijska sredstva
HRP20100384T1 (hr) Antibakterijski derivati kvinolina
HRP20090050T3 (hr) Novi derivati pirolifin-3, 4-dikarboksamida
MX2009003051A (es) Derivados de quinolinona.